Efficacy of Upadacitinib as a Second-line JAK Inhibitor in Ulcerative Colitis: A Case Series
Description
Upadacitinib, a recently approved Janus kinase (JAK) inhibitor specific for JAK1, may be a promising candidate in patients with ulcerative colitis (UC) who present no response or intolerance to first-line JAK inhibitors. We assessed the therapeutic